Pinealon

Pinealon (Glu-Asp-Arg, or EDR) is a synthetic tripeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a brain-specific bioregulator peptide, designed to target neuronal tissue and modulate gene expression related to neuroprotection, cognitive function, and circadian rhythm regulation. The name derives from its proposed tropism for pineal and cerebral tissue, though its effects are not limited to the pineal gland.

Like other Khavinson bioregulator peptides (Epitalon, Cartalax), Pinealon belongs to the class of ultra-short peptides hypothesized to interact directly with DNA to modulate gene expression. It has been studied primarily in Russian academic institutions, with the evidence base consisting largely of in vitro cell culture studies and limited animal work. Pinealon is available as a supplement in some markets and is sometimes used in combination with Epitalon for purported synergistic anti-aging and neuroprotective effects.

Pinealon's proposed primary mechanism involves direct DNA interaction in neuronal cells. According to the bioregulator peptide model, the Glu-Asp-Arg sequence binds to complementary nucleotide sequences in gene promoter regions, modulating transcription of neuroprotective genes. In vitro studies have demonstrated that Pinealon upregulates anti-apoptotic Bcl-2 expression while downregulating pro-apoptotic Bax and caspase-3, shifting the cellular balance toward survival under hypoxic stress.

The peptide also influences neuronal differentiation markers. It increases expression of GAP-43 (growth-associated protein 43), a marker of neurite outgrowth and synaptic plasticity, and synaptophysin, a synaptic vesicle protein involved in neurotransmitter release. These effects suggest promotion of neuronal connectivity and synaptic function. Additionally, Pinealon has been reported to influence melatonin synthesis pathways, consistent with its proposed pineal tropism, though the molecular details of this interaction remain incompletely characterized. The tripeptide's small size (404 Da) theoretically allows blood-brain barrier penetration, though BBB permeability has not been directly measured.